|
Company |
Business Focus |
ALIGN
TECHNOLOGY, INC. |
Align
Technology designs, manufactures and markets the Invisalign System,
a proprietary new method for treating malocclusion, or the misalignment
of teeth. The System corrects malocclusion using a series
of clear, removable appliances that gently move teeth to a desired
final position. Align Technology went public in 2001. |
AMIRA
MEDICAL, INC . |
Amira
Medical develops, manufactures and marketed the AtLast integrated
blood glucose measurement system that featured painless, convenient
alternate site blood collection and glucose measurement.
AtLast was launched in the U.S. market late in 1999. Amira
was acquired by Roche Diagnostics in 2001. |
| CARDIAC
PATHWAYS CORPORATION |
Cardiac Pathways Corporation designs and develops minimally invasive,
clinically superior systems to diagnose and cure cardiac tachyarrhythmias,
a serious medical condition characterized by a rapid heart rate.
These systems speed the diagnosis of tachyarrhythmias by
providing superior mapping and ablation capabilities. The Company
went public in 1996 and was acquired by Boston Scientific in 2001.
|
CARDIOVASC,
INC.
|
Cardiovasc
develops, manufactures and markets advanced cardiovascular devices
featuring a unique bioactive coating, P15, that promotes rapid endothelialization
of medical implants and long-term biocompatibility. The Company
is currently marketing its initial coronary stent graft in Europe
and seeking US FDA approval. |
| CBYON,
INC. |
CBYON
develops, manufactures and markets advanced software for surgical
navigation applications running on common operating system platforms.
The Company’s first product will allow the physician to merge
a variety of image data sets with real time endoscopic images, preserving
and enhancing three-dimensional localization of the working end
of the surgical tool. |
| DECIBEL
INSTRUMENTS, INC. |
Decibel
developed, manufactured and marketed hearing aids that can be custom
fitted and delivered to the patient within one hour. Decibel’s novel
articulated joint technology allows unsurpassed patient comfort.
The Company sold directly to the consumer through agreements
with existing retail channels. Decibel was liquidated
in 1999. |
| ENTERIC
MEDICAL TECHNOLOGIES, INC. |
Enteric
Medical Technologies designs, develops, and plans to market novel
minimally invasive implant systems for the treatment of gastroesophageal
reflux disease (GERD). The Company has developed a new approach
for GERD treatment that has the potential to dramatically alter
current surgical intervention. Their approach involves injection
of a non-erodable biocompatible polymer submucosally in the lower
section of the esophageous. Enteric Medical was acquired
by Boston Scientific in 2002. |
| FOX
HOLLOW TECHNOLOGIES, INC. |
Fox
Hollow Technologies develops, designs and plans to market a novel
percutaneous atherectomy device for optimal debulking of occluded
coronary arteries. The Fund received shares in
Fox Hollow following the acquisition of Reflow, a portfolio company
that planned to develop a catheter-based system for the treatment
of chronic total occlusions (CTO) in coronary arteries. |
| MEDIVANCE,
INC. |
Medivance
develops, manufactures and markets the noninvasive Arctic Sun patient
temperature management system for hypothermia treatment in neuro
applications such as stroke and fever control, and to improve outcomes
for heart attack and cardiac arrest patients. |
| NATUS
MEDICAL, INC. |
Natus
develops, manufactures and markets proprietary electronic medical
instruments and related disposables for the perinatal sector of
the hospital equipment market, including obstetrics, neonatology
and pediatrics. The Company's devices are designed for broad
screening applications such as hearing impairment and risk of jaundice.
Natus went public in 2001. |
| OMNICELL
TECHNOLOGIES, INC. |
OmniCell
Technologies designs, manufactures, markets and services automated
point‑of‑use supply stations and software that improves the management
and control of supplies in hospitals. The Company's first
product, the OmniCell Supply Management System, provides unique
automated medical supply dispensing, inventory and billing information
capabilities designed to increase hospital productivity and reduce
lost charges, labor, and other materials management costs.
OmniCell went public in 2001. |
| PERCLOSE,
INC. |
Perclose,
Inc. designs, manufactures and markets proprietary suturing devices
to close arterial access puncture sites following vascular catheterization
procedures. Their products have demonstrated significant
clinical and economic benefits by obtaining rapid, sustained hemostasis
(closure) of the arterial access site in fully anticoagulated patients.
The Company went public in 1995 and was acquired by Abbott in 1999.
|
| PHARMASONICS,
INC. |
Pharmasonics
develops, manufactures and plans to market power ultrasonic interventional
cardiology devices to address the problem of restenosis in coronary
arteries. Their lead product aims to reduce the rate of restenosis
after intervention by applying a therapeutic level of ultrasound
radiation to the target lesion. Their pivotal trial showed restenosis
rates were not significantly different from controls, and the Company
was shut down in mid 2003. |
| PHORMAX,
INC . |
Phormax
designs, develops and plans to market low cost computed radiography
(CR) instruments based on their patented laser scanning technology.
The Company decided to merge with Alara Medical in the second
quarter of 2002. The CR product is set for 510(k) approval
in late 2003. |
| PHYSIOMETRIX,
INC. |
Physiometrix
designs, manufactures and markets proprietary diagnosis and monitoring
products for the neurophysiology market. Their main product
is an advanced neurological signal measurement and processing system,
the Patient State Analyzer, for depth of anaesthesia monitoring.
The Company went public in 1996. |
| RITA
MEDICAL SYSTEMS, INC. |
RITA
Medical Systems designs, develops, manufactures, and markets novel,
minimally invasive surgical ablation systems for the treatment of
solid organ tumors. RITA’s initial products will target primary
and metastatic tumors of the liver and other organs, with newer
devices planned for bone cancer. RITA Medical went public in 2000.
|
| THERUS,
INC . |
Therus
is developing a noninvasive high intensity focused ultrasound device
to quickly, safely and easily close femoral access sites following
interventional cardiology procedures. Therus entered into
an option agreement with Boston Scientific in 2001 that allows for
the eventual acquisition of the Company following product development
milestones. |
| TISSUELINK
MEDICAL, INC |
TissueLink
designs, develops and markets disposable surgical products to cut,
shrink, and seal tissue using RF energy and saline as a ‘liquid
electrode’. Initial sales of their first products for thoracic
surgery commenced in the first quarter of 2001, with other products
for orthopedic and general surgery launched in 2002. |
| ULTRACISION,
INC. |
UltraCision
designs, develops, manufactures, and markets advanced minimally
invasive surgical instruments based on its proprietary core technologies
in ultrasound energy and harmonic motion. The Company’s Harmonic
Scalpel system is a line of powered laparoscopic surgical instruments
utilizing highly directed ultrasound energy to incise tissue and
coagulate bleeding vessels with precision and safety. The Company
was acquired by Johnson & Johnson in 1995.
|
| VENTRO
(NEXPRISE, INC.) / SPECIALTYMD.COM |
SpecialtyMD.com
developed an Internet portal for education and marketing to select
physicians such as cardiologists. The Company was acquired by Ventro
(now Nexprise) in 1999. |
| VIDAMED,
INC. |
VidaMed,
Inc. designs, develops, manufactures and markets cost-effective
and clinically efficacious devices for the treatment of significant
urologic conditions. VidaMed's initial focus is the treatment
of Benign Prostatic Hyperplasia (BPH) using its proprietary TransUrethral
Needle Ablation (TUNA™) system, a catheter-based radiofrequency
ablation device, allowing the urologist to precisely target and
ablate culprit tissue, while leaving adjacent structures such as
the urethra and bladder unharmed. The Company went public in 1995
and was acquired by Medtronic in 2001. |
| |
|
